Alvotech
20 articles with Alvotech
-
Alvotech Welcomes Positive CHMP Opinion for AVT02, a Proposed Biosimilar to Humira®
9/17/2021
Alvotech today welcomed the positive opinion of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the approval of Alvotech‘s high-concentration AVT02 (100 mg/mL), a proposed biosimilar to Humira® (adalimumab).
-
Alvotech Initiates Clinical Studies for AVT04, a Proposed Biosimilar to Stelara® (Ustekinumab)
7/6/2021
Alvotech today announced that the first patient has been dosed in the comparative, confirmatory efficacy and safety clinical study (AVT04-GL-301) for AVT04.
-
Alvotech Bondholders Convert More Than $100m at Pre-Money Valuation of $2.7bn
6/25/2021
Alvotech Holdings SA announced that it has entered into an amendment and restatement agreement with bondholders of its $300m covertible bond issued on December 14, 2018.
-
Alvotech Seeks to End AbbVie’s Wrongful Monopoly on Humira and Bring Affordable Arthritis Treatment to U.S.
5/11/2021
Alvotech today filed a federal lawsuit (Case 1:21-cv-00589) seeking to end the monopoly that pharmaceutical giant AbbVie has long-maintained on the adalimumab market, sold as Humira.
-
AbbVie has filed a legal complaint against Icelandic pharmaceutical company Alvotech for the latter’s alleged misappropriation of trade secrets involving the development of a generic version of AbbVie’s rheumatoid arthritis drug Humira.
-
Alvotech Completes Second Round of a US$ 100m Private Placement
3/15/2021
Biopharmaceutical company Alvotech has successfully completed a second round of its US$ 100 million private placement, for US$ 35 million.
-
Alvotech, Alvotech & CCHT Biopharmaceutical and Yangtze River Pharmaceutical Agree on an Exclusive Biosimilar Partnership in China
11/24/2020
Through this partnership, a powerhouse has been created in one of the world’s largest biologics markets, designed to improve patient access to high quality biosimilars in China°
-
Alvotech Announces That the U.S. FDA and EMA Have Accepted Regulatory Submissions for AVT02, a Proposed Biosimilar to HUMIRA® (adalimumab)
11/19/2020
Alvotech Announces That the U.S. FDA and EMA Have Accepted Regulatory Submissions for AVT02, a Proposed Biosimilar to HUMIRA® (adalimumab) Alvotech is developing AVT02 as a proposed biosimilar to HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms AVT02 is highly similar to its reference product in terms of structure and function The pharmacokinetic (PK) similarity study for AVT02 (AVT02-GL-101) has met its primary objectives
-
Alvotech Announces Private Placement Financing - Oct 27, 2020
10/27/2020
Biopharmaceutical company Alvotech announced that its parent company, Alvotech Holdings SA, has successfully completed a $65 million private placement round.
-
Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market
8/5/2020
The collaboration is one of the broadest partnerships within the U.S. biosimilar industry to date to accelerate improved patient access for high quality biosimilar medicines in the U.S. biosimilar industry
-
JAMP Pharma Group signs a landmark partnership agreement for the commercialization of five biosimilar medicines in Canada
1/14/2020
Canadian pharmaceutical company JAMP Pharma Group has signed an exclusive agreement with global speciality biopharmaceutical company Alvotech for the Canadian commercial rights to five biosimilars.
-
Alvotech and STADA Agree on Strategic Biosimilar Partnership
11/6/2019
Biopharmaceutical company Alvotech and global pharmaceutical company STADA Arzneimittel AG announced that they have entered into an exclusive strategic partnership for the commercialization of seven biosimilars in all key European markets and selected markets outside Europe.
-
Yas Holding Invests in Alvotech and Agrees on a Strategic Partnership for Biosimilar Candidates
11/4/2019
Biopharmaceutical company Alvotech announced that Abu Dhabi-based investment company, Yas Holding, has acquired a 2.5% stake in their business and signed an agreement for the exclusive partnership and supply of three Alvotech biosimilar candidates, which Yas Holding will commercialize in the MENA region.
-
Alvotech Selects Veeva Vault QMS to Modernize Quality Processes
9/5/2019
Biopharmaceutical company to unify quality management on a single platform for greater efficiency and compliance
-
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA®
3/13/2019
Alvotech's AVT02 is being developed as a biosimilar of the HUMIRA® high-concentration (100mg/mL) product, expected to be more convenient for patients, compared to biosimilar competitors
-
Fuji Pharma Invests in Alvotech for US$50 Million
12/17/2018
Alvotech and Fuji Pharma recently announced an exclusive agreement for development and commercialization of biosimilars in Japan.
-
Rasmus Rojkjaer Appointed CEO Of Alvotech
8/4/2017
-
Former Alvotech Exec Jumps Ship to Pfenex as CEO
8/3/2017
-
Alvotech Opens State-Of-The-Art Biosimilar Facility In Iceland
6/8/2016
-
Alvotech Announces Acquisition Of Baliopharm
5/19/2016